

# BlackRock European Fund

As at 31 May 2022

# BLACKROCK


- The investment decision is yours. You should not invest in the investment product unless the licensed investment advisor who introduces it to you has advised you that it is suitable for you and has explained why, including how buying it would be consistent with your investment objectives.
- Investment in a Fund may involve a high degree of risk and may not be suitable for all investors. Past performance is not indicative of future results. The value of a Fund can be volatile and could go down substantially within a short period of time. It is possible that the entire amount of your investment could be lost.
- Funds which invest in emerging markets, specific markets or sectors should be regarded as higher risk than funds following a more diversified policy. Please pay attention to the "Special Risk Considerations" section in the Prospectus for risks associated with investing in emerging markets, specific markets or sectors.

## A-Share Cumulative Performance in USD

	YTD	6 Months	1 Year	3 Years	5 Years	Since Launch
	%	%	%	%	%	%
<b>Fund</b>	<b>-25.7</b>	<b>-24.7</b>	<b>-21.4</b>	<b>36.9</b>	<b>29.1</b>	<b>533.9</b>
MSCI Europe (net)	-12.0	-6.2	-9.8	23.0	22.2	547.9

## A-Share Calendar Year Performance in USD

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
	%	%	%	%	%	%	%	%	%	%	%	%	%	%
<b>Fund</b>	<b>19.2</b>	<b>31.5</b>	<b>29.7</b>	<b>-18.5</b>	<b>+21.4</b>	<b>-8.5</b>	<b>-0.4</b>	<b>-9.7</b>	<b>+26.9</b>	<b>+22.7</b>	<b>-13.2</b>	<b>+5.4</b>	<b>+42.6</b>	<b>-43.0</b>
MSCI Europe (net)	16.3	5.4	23.8	-14.9	+25.5	-0.4	-2.8	-6.2	+25.2	+19.1	-11.1	+3.9	+35.8	-46.4



## Fund Data


Manager	Nigel Bolton
Inception	30.11.93
Currency	US\$
Total Fund Size (m)	US \$1,472.2
Annual Management Fee	1.50%
Initial Charge	5%

## 10 Largest Holdings (%)


NOVO NORDISK A/S	6.0
LVMH MOET HENNESSY LOUIS VUITTON SE	5.8
ASML HOLDING NV	5.4
LONZA GROUP AG	5.1
ASTRAZENECA PLC	5.0
RELX PLC	4.0
LINDE PLC	3.9
DSV A/S	3.8
ROYAL UNIBREW A/S	3.4
SIKA AG	3.3
<b>Total</b>	<b>45.6</b>

## Composition of Fund

### Country



### Sector



## Investment Objective

The European Fund seeks to maximise total return. The Fund invests at least 70% of its total assets in the equity securities of companies domiciled in, or exercising the predominant part of their economic activity in, Europe.

## Fund Manager's Report

### Performance Overview

- In a quiet month for company newsflow, market participants continue to grapple with the implications of slowing economic growth, rising food and energy prices, high spot inflation numbers, tight labour markets, and hawkish central banks.
- The European market fell modestly overall, and well-owned, higher quality and higher growth companies generally underperformed in a continuation of a theme seen throughout much of the year to date. The fund underperformed the index driven primarily by selection effect.
- The level of uncertainty in markets remains elevated. Our focus remains squarely on the fundamentals of businesses where we believe portfolio companies have better balance sheets, higher margins, lower capital intensity, and more resilient supply chains than the overall market – attributes that should serve them well in this environment.

### Sectors

- All sectors except three were negative during the month – with energy the stand out gainer followed by financials and communication services.
- The biggest detractor from a sector perspective was in energy, where the underweight was a headwind to returns.
- The underweight to consumer staples benefitted relative returns.

### Stocks

- As outlined above, there was minimal stock specific news this month. The fund's biggest detractors were high quality businesses seeing strong operational performance and positive earnings momentum – but met with multiple de-ratings.
- Specialty chemical companies Sika and IMCD shares came under pressure. IMCD reported very strong results in April, with organic growth 18% ahead of estimates, margin expansion year-on-year, a 30% operating profit beat, and comments from the management team that they expect to continue to grow profits organically through the remainder of this year.
- Teleperformance also detracted without any specific news.
- Novo Nordisk weighed on portfolio returns. There was one piece of newsflow concerning pricing of a competitor drug – though this was largely in line with expectations and doesn't appear to have been the cause of the negative share price performance. Operationally the company is progressing very well having positively pre-released Q1 results and raised guidance in April. We continue to see this as a best in class, value creating and resilient business.
- The fund also suffered by not owning TotalEnergies or Shell – both large index constituents in the energy sector. The portfolio's position in Tenaris – producer of steel tubes used in drilling – helped to partially offset this drag.
- Some of the benchmark's large cap defensives sold off during the risk-on bounce later in the month. Not holding Roche and Nestle was positive in this context.
- The share price pressure on Straumann abated this month – aiding relative returns. The company announced a small acquisition which will expand their clear aligners footprint in select European markets; and the CEO confirmed that they are not seeing any evidence of consumer weakness. Aside from these points there has been no material stock specific news since their announcement of very strong Q1 results in April.

### Changes

- We added a position in AstraZeneca. The company has a leading oncology franchise diversified across 5 key brands. It also has best-in-class non-oncology drugs in respiratory and a strong cardiovascular franchise. The company has high quality earnings and we expect improving margins and a rich catalyst calendar.
- We consolidated our position in Safran into competitor MTU. Whilst we continue to like both businesses, we see marginally more attractive prospects for MTU given its pure-play engine exposure and the greater potential for it to expand its market share over the next decade. Furthermore, we expect MTU to require minimal headcount expansion this year relative to Safran, which made lay-offs over the last two years which will likely need to be partially reversed.
- We exited the remainder of our position in Logitech given its exposure to a potential deterioration in consumer spending and evidence that its video collaboration business is not progressing as well as we had anticipated.

### Positioning

- At the end of the month the largest overweights were in industrials, IT, and healthcare. The most significant underweights were in consumer staples and financials.

The Fund investment objective was changed on 20 June 2008.

Effective 28 April 2008, Merrill Lynch International Investment Funds (MLIIF) changed its name to BlackRock Global Funds (BGF). Prior to such date the Fund was known as MLIIF European Fund.

BlackRock European Fund is the abbreviated name of BlackRock Global Funds – European Fund.

Effective 1 July 2002, Mercury Selected Trust (MST) changed its name to Merrill Lynch International Investment Funds (MLIIF). Prior to such date the Fund was known as MST European Fund.

Sources: BlackRock Investment Management (UK) Limited and Datastream. Performance is shown as at 31 May 2022 in US\$ on a NAV to NAV price basis with income reinvested. Fund performance figures are calculated net of fees. The above Fund data is for information only.

Investment involves risk. Past performance is not necessarily a guide to future performance. The value of investments and the income from them can fluctuate and is not guaranteed. The investment returns are denominated in Euro. US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar/Euro exchange rate. Investors may not get back the amount they invest. Individual stock price/figure does not represent the return of the Fund. For Hong Kong investors, please refer to the BGF Prospectus for details, including risk factors. Issued in Hong Kong by BlackRock (Hong Kong) Limited.

This advertisement (or sales material) has not been reviewed by the Securities and Futures Commission of Hong Kong.

In Singapore, this information is issued by BlackRock Investment Management (Singapore) Limited. For the purposes of distribution in Singapore, this document forms part of the prospectus for BGF (which is an information memorandum as defined in the Securities and Futures Act). In Singapore, the fund referred to in this document may be offered to institutional investors under section 304 and accredited investors under section 305 of the Securities and Futures Act only.

## BlackRock (Hong Kong) Limited

Address: 16/F Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

Tel: +852 3903 2800 Fax: +852 3903 2900 Website: <http://www.blackrock.com.hk>

# 貝萊德歐洲基金

截至 2022年5月31日止




1. 投資決定在於你本人。除非將該投資產品介紹給你的持牌投資顧問已指出該產品適合你本人及已向你說明該產品為何及如何符合你的投資目標，否則您不應投資於該產品。
2. 投資基金可能涉及高風險，並可能不適合所有投資者。過往業績並不代表將來的表現，基金價格及其收益可升可跌，且可於短期內反覆，投資者並可能會損失所有投資金額。
3. 投資者應注意投資於某些較小型及新興市場、特定市場或行業的基金為風險較高的基金。投資者請注意貝萊德全球基金章程的“特殊風險考慮因素”一節有關投資於新興市場，特定市場或行業的基金的風險。

## A 股基金累積表現 (美元)

	年初至今 %	六個月 %	一年 %	三年 %	五年 %	成立至今 %
本基金	-25.7	-24.7	-21.4	36.9	29.1	533.9
MSCI歐洲指數 (淨值)	-12.0	-6.2	-9.8	23.0	22.2	547.9

## A 股基金年度表現 (美元)

	2021 %	2020 %	2019 %	2018 %	2017 %	2016 %	2015 %	2014 %	2013 %	2012 %	2011 %	2010 %	2009 %	2008 %
本基金	19.2	31.5	29.7	-18.5	+21.4	-8.5	-0.4	-9.7	+26.9	+22.7	-13.2	+5.4	+42.6	-43.0
MSCI歐洲指數 (淨值)	16.3	5.4	23.8	-14.9	+25.5	-0.4	-2.8	-6.2	+25.2	+19.1	-11.1	+3.9	+35.8	-46.4



## 投資目標

貝萊德歐洲基金以盡量提高總回報為目標。基金將總資產至少70%投入於在歐洲註冊或從事大部分經濟活的公司之股權證券。

## 基金經理報告

### 表現概述

- 月內，企業消息淡靜，市場人士繼續努力應對以下因素帶來的影響：經濟增長放緩、食品和能源價格上漲、即期通脹數據偏、勞工市場緊繃和央行立場強硬。
- 整體來說，歐洲市場輕微回落，在同一主題於年初至今大部份時間持續的情況下，佔重倉的優質和高增長企業普遍表現失色。基金表現遜於指數，主要源於選股策略。
- 市況仍然高度不明朗。我們繼續明確聚焦於公司的基本因素：與整體市場相比，我們所持有的公司擁有較佳的財政狀況，利潤率較高，資本密集度較低，而且供應鏈較為穩健，這些特性應可在目前環境下為公司提供良好支持。

### 行業

- 所有行業均在月內錄得負回報，但有三個行業屬於例外：能源股顯著上升，其次為金融和通訊服務。
- 從行業角度來看，能源股最淡表現，因為基金對能源股持偏低比重對回報構成阻力。
- 相反，基金對基本消費品業持偏低比重有利相對回報。

### 股票

- 如上所述，本月有關個股的消息不多。最利淡基金表現的持倉為優質企業，這些企業展現強勁營運表現和正面盈利動力，但面對估值下調。
- 專用化學品公司Sika和IMCD的股價受壓。IMCD在4月份公佈的業績非常強勁：內部增長超過預期18%；利潤率按年擴張；營運利潤較預期高出30%。該公司管理團隊表示，預期將在本年餘下時間內持續透過固有業務取得利潤增長。
- Teleperformance並無任何個股消息，但亦拖累基金表現。
- 諾和諾德 (Novo Nordisk) 使投資組合回報受壓。市場傳出一項有關該公司競爭對手藥物的定價消息，但大致與預期相符，似乎並非利淡股價表現的原因。該公司在4月預先發佈正面的第一季業績並調高盈利指引，在營運方面進展順利。我們繼續認為諾和諾德是強勁的價值創造企業，在同類企業中表現最佳。
- 基金並無持有TotalEnergies及Shell這兩隻能源業大型指數成份股，亦因此表現受壓，但投資組合持有鑽井用鋼管生產商Tenaris有助局部抵銷上述負面影響。
- 在月底市場承險氣復甦期間，部份基準指數大型防守股遭拋售。在此情況下，基金並無持有羅氏 (Roche) 和雀巢 (Nestle) 帶來貢獻。
- Straumann股價承受的壓力在本月有所舒緩，亦有助提升相對回報。該公司公佈有關一項小型收購的消息，這將擴大其在個別歐洲市場牙科牙套業務的清晰定位，另外行政總裁亦確認並無任何消費回軟的跡象。除了上述消息外，自從該公司在4月發佈非常強勁的第一季業績以來，並無出現任何重大個股消息。

### 變動

- 基金增持阿斯利康 (AstraZeneca)。該公司經營領先的腫瘤藥物業務，旗下擁有五個主要品牌，以及同類最佳的呼吸系統非腫瘤藥物和強勁的心血管藥物業務。阿斯利康擁有優質盈利，預期利潤率將會改善，而且在未來兩年獲得大量刺激因素推動。
- 我們將Safran的持倉整合至其競爭對手MTU。我們仍看好兩家公司，但由於MTU專營引擎業務，而且在未來十年擴大市場份額的潛力較大，我們認為MTU前景的吸引力略勝一籌。此外，與Safran相比，我們預計MTU在本年需要增聘的員工人數不多，相反Safran在過去兩年裁員，很可能需要重新招聘部份職位。
- 鑑於羅技 (Logitech) 面臨消費開支可能轉趨的風險，而且有跡象顯示其視訊協作業務進展不如我們預期，我們沽清餘下的持倉。

### 配置

- 基金於月底對工業、資訊科技和醫療保健業持最大偏高比重。另一方面，基金對基本消費品和金融業持最大偏低比重。

## 基金資料


基金經理	Nigel Bolton
成立日期	30.11.93
報價貨幣	美元
基金總值 (百萬)	1,472.2美元
每年管理費	1.50%
首次認費	5%

## 十大持股比重 (%)


NOVO NORDISK A/S	6.0
LVMH MOET HENNESSY LOUIS VUITTON SE	5.8
ASML HOLDING NV	5.4
LONZA GROUP AG	5.1
ASTRAZENECA PLC	5.0
RELX PLC	4.0
LINDE PLC	3.9
DSV A/S	3.8
ROYAL UNIBREW A/S	3.4
SIKA AG	3.3
<b>Total</b>	<b>45.6</b>

## 基金投資分佈

### 國家



### 行業



基金的投資目標於 2008 年 6 月 20 日已被更改。

於 2008 年 4 月 28 日，美林國際投資基金已更名為貝萊德全球基金。在上述日期前，此基金名為美林歐洲基金。

貝萊德歐洲基金乃貝萊德全球基金 - 歐洲基金之簡稱。

於 2002 年 7 月 1 日，水星 MST 基金已更名為美林國際投資基金。在上述日期前，此基金名為水星 MST 歐洲基金。

資料來源：BlackRock Investment Management (UK) Limited 及 Datastream。基金表現截至 2022 年 5 月 31 日為止，以美元按資產淨值比資產淨值基礎計算，將收入再作投資。基金表現數據的計算已扣除費用。上述基金表現僅作參考之用。

投資涉及風險。過往業績並不代表將來的表現，基金價格及其收益可升可跌，並不能保證。投資收益以歐元計算。因此，以美元 / 港元作出投資的投資者，需承受美元 / 港元 / 歐元兌換率的波動的風險。投資者可能無法取回原本投資金額。個別股票價格並不代表本基金的回報。香港投資者欲知有關詳情，請參考貝萊德全球基金章程，包括風險成份。資料由貝萊德 (香港) 有限公司所發佈。

此廣告 (或銷售資料) 並未獲香港證監會所審閱。

在新加坡，資料由 BlackRock Investment Management (Singapore) Limited 所發佈。在新加坡分銷本基金，此文件將被納入貝萊德全球基金售股章程的一部份 (即證券及期貨條例所定義的資料備忘錄)。

在新加坡，此文件所提及的基金只可售予證券及期貨條例第 304 條定義的機構投資者及第 305 條定義的認可投資者。

## 貝萊德 (香港) 有限公司

地址：香港中環皇后大道中 2 號長江集團中心 16 樓

電話：+852 3903 2800 傳真：+852 3903 2900 網址：http://www.blackrock.com.hk